Treatment-Induced Phenotypic Reprogramming in Prostate Cancer

Grants and Contracts Details


Dr. Mellon will be the consortium PI at the University of Kentucky. Her effort on this project will be devoted to supervising the student through regularly scheduled skype or phone meetings to evaluate their progress. Dr. Mellon will work in conjuncture with Dr. Natasha Kyprianou on the verification of deliverables as outlined below for the Specific Aims 2 and 3 which will be conducted by the graduate research assistant. Ms. Diane Begemann, will continue to conduct research on the project “Treatment-induced Phenotypic Reprogramming in Prostate Cancer” under the direction of Dr. Isabel Mellon and continued mentorship of Dr. Natasha Kyprianou. She is responsible for developing the Cabazitaxel resistant prostate cancer cell models and she will be performing the in vitro mechanistic studies dissecting the role of kinesins and centrosome amplification in the response to taxane and kinesin inhibition (Specific Aims 2 and 3). Regularly scheduled meeting will be held with Drs. Mellon and Kyprianou to evaluate progress on the above mentioned deliverables.
Effective start/end date11/22/194/30/20


  • Mount Sinai: $50,300.00


Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.